latest news releases from the newsroom
Peab to build a new motorway in Dalarna
FOERSLOEV, Sweden, Oct. 20, 2003 (PRIMEZONE) -- Peab has won the contract to build 12 kilometres new motorway from Falun to Ornas in the county of Dalarna. The client is the Swedish National Road Association and the contract amounts SEK 300 million.
COLT Telecom Group plc
COLT Secures Major Financial Customers For Managed IP VPN Service
LONDON, Oct. 20, 2003 (PRIMEZONE) -- COLT Telecom Group plc (Nasdaq:COLT) (LSE:CTM) has significantly strengthened its position in the European IP Virtual Private Network market, having signed over 300 of SWIFT's financial services members across Europe in just 8 months. COLT has a multi-million euro contract with SWIFT, an industry body that supplies secure messaging services to 7,000 financial companies worldwide.
Ahold appoints Jim Lawler as Chief Human Resource Officer
ZAANDAM, The Netherlands, Oct. 20, 2003 (PRIMEZONE) -- The Ahold (NYSE:AHO)(Other OTC:AHODF) Corporate Executive Board today announced it has appointed Jim Lawler as Chief Human Resource Officer, effective immediately. He succeeds Arthur Brouwer, who was recently appointed Chief Business Support Officer.
Tornet's Board recommends the shareholders to accept the offer
STOCKHOLM, Sweden, Oct. 20, 2003 (PRIMEZONE) -- After the publication of Fastighets AB Tornet's interim report for January-June 2003, Lehman Brothers Real Estate Partners L.P. (LBREP) and Ratos AB initiated a due diligence-process with a view to presenting a public offer for all shares in Tornet. The presentation of a public offer was conditional on the outcome of the due diligence-process and on ensuring financing. The Board of Directors made the assessment that the intended offer could be of interest to the shareholders and a due diligence-process was therefore approved. No information suited to affect, to a not insignificant extent, the previous valuation of Tornet's shares has been communicated to LBREP or Ratos.
SkyePharma Welcomes FDA Approval of Additional Indication for Paxil CR
LONDON, Oct. 20, 2003 (PRIMEZONE) -- SkyePharma PLC (Nasdaq:SKYE) (LSE:SKP) welcomes the recent announcement by its partner GlaxoSmithKline (NYSE:GSK), that the US Food & Drug Administration ("FDA") has approved an additional therapeutic indication for Paxil CR(TM) (paroxetine hydrochloride Controlled Release) for the treatment of social anxiety disorder. Paxil CR(TM) is already approved and on the market in the US for the treatment of depression, panic disorder and, most recently, premenstrual dysphoric disorder (PMDD). SkyePharma developed the controlled release formulation used in Paxil CR(TM) and receives a royalty on GlaxoSmithKline's sales.
Trintech Group Plc
Whitbread Group PLC Selects Trintech's ReconNET Suite to Automate Reconciliation and Improve Cash Controls
LONDON and TEXAS, Oct. 20, 2003 (PRIMEZONE) -- Trintech (Nasdaq:TTPA) (Prime Standard:TTP), a leading provider of transaction management and payment infrastructure solutions, today announced that Whitbread Group PLC, the UK's leading hotel, leisure and restaurants group, has selected ReconNET 6.6, ReconNET Online and ExecuNET to automate reconciliation of its deposit and credit card transactions, streamline its cash management processes, and provide effective risk management and reporting across its businesses.